Cloudz™ T Cell Activation Kit – CD3/CD28

The Cloudz T Cell Activation Kit

The Cloudz T Cell Activation Kit - CD3/CD28 contains non-magnetic, dissolvable microparticles that are manufactured under GMP controls and conjugated with the common T cell-activating antibodies, CD3 and CD28. This kit improves T cell expansion and simplifies cell recovery for ex vivo manufacturing, while also providing safety and efficacy advantages over current bead-based T cell activation methods.

Features

  • CD3/CD28 antibody-conjugated microparticles
  • Release buffer dissolves particles in < 10 seconds
  • Manufactured under GMP controls

Benefits

  • Ideal for CAR T or T cell therapeutic manufacturing
  • Robust T cell activation
  • Simplified recovery of cells
  • Improved product purity over magnetic activation techniques

Cloudz CD3/CD28 Protocol

Cloudz CD3/CD28 Protocol

Advantages of Cloudz CD3/CD28 for Cell Therapy

Robust CD3+ T Cell Expansion

Cloudz CD3/CD28 induces 8-9 population doublings during a 9-day ex vivo culture of human CD3+ T cells or PBMCs.

Robust CD3+ T Cell Expansion

Order Today or Request More Information

 

Fill out this form and a sales representative will contact you with technical and pricing information.

Favorable Performance Over Magnetic Bead and Soluble Antibody

With comparable expansion rates to existing bead and soluble antibody activating protocols, Cloudz CD3/CD28 offers additional manufacturing advantages, including single administration use and easier cell collection.

Improved CD8+ T Cell Expansion

Improved CD8+ T Cell Expansion

Cloudz CD3/CD28 improves CD8+ effector T cell expansion without compromising expansion rates of CD4+ T cells.

Improved CD8+ T Cell Expansion

Externally Validated

Independent analysis of Cloudz CD3/CD28 shows improved expansion over alternative expansion technologies. *Results disclosed with permission of external collaborator.

Independent analysis of Cloudz CD3/CD28

Improved T Cell Transduction

Cloudz CD3/CD28 shows improved CAR transduction in CD3+, CD4+, and CD8+ T cells compared to bead-based technologies. *Results disclosed with permission of external collaborator.

Cloudz CD3/CD28